These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28548608)

  • 21. European Union centralised procedure for marketing authorisation of oncology drugs: an in-depth review of its efficiency.
    Netzer T
    Eur J Cancer; 2006 Mar; 42(4):446-55. PubMed ID: 16129598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulatory experience of handling Risk Management Plans (RMPs) for medicinal products in the EU.
    Butler D; Vucic K; Straus S; Cupelli A; Micallef B; Serracino-Inglott A; Borg JJ
    Expert Opin Drug Saf; 2021 Jul; 20(7):815-826. PubMed ID: 33843379
    [No Abstract]   [Full Text] [Related]  

  • 23. Potential Procedural Efficiencies and Challenges of Combining Multiple Type II Variations into a Single EU-RMP.
    Marshall R; Atuah KN; Tekumalla SH
    Pharmaceut Med; 2020 Feb; 34(1):1-5. PubMed ID: 32048215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of studies evaluating the effectiveness of risk minimisation measures in Europe using the European Union electronic Register of Post-Authorization Studies.
    Vora P; Artime E; Soriano-Gabarró M; Qizilbash N; Singh V; Asiimwe A
    Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):695-706. PubMed ID: 29663572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Better medicines for children: European measures].
    van den Berg H; Taminiau JA
    Ned Tijdschr Geneeskd; 2008 Jul; 152(27):1537-40. PubMed ID: 18681365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval.
    Giezen TJ; Mantel-Teeuwisse AK; Straus SM; Egberts TC; Blackburn S; Persson I; Leufkens HG
    Drug Saf; 2009; 32(12):1175-87. PubMed ID: 19916584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
    Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
    Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The licensing of medicines in the UK.
    Drug Ther Bull; 2009 Apr; 47(4):45-8. PubMed ID: 19357299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New European commission regulation on variations to the terms of marketing authorization for medicinal products and its impact on Croatian legislation.
    Martinac AI; Tomić S; Simicić M
    Arh Hig Rada Toksikol; 2010 Sep; 61(3):311-22. PubMed ID: 20860972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Experimental testing of centrally authorised medicinal products. The CAP programme].
    Giess S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1169-72. PubMed ID: 25159224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biosimilars: pharmacovigilance and risk management.
    Zuñiga L; Calvo B
    Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):661-9. PubMed ID: 20583204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk Management Plans: are they a tool for improving drug safety?
    Frau S; Font Pous M; Luppino MR; Conforti A
    Eur J Clin Pharmacol; 2010 Aug; 66(8):785-90. PubMed ID: 20577875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interest of pharmacoepidemiology in pharmacovigilance: Post-authorization safety studies in regulatory pharmacovigilance activity.
    Abou Taam M; Ferard C; Rocle P; Maison P
    Therapie; 2019 Apr; 74(2):301-306. PubMed ID: 30704766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [EU law on marketing authorization of medicines. History, current state of development and perspectives].
    Nettesheim M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):705-12. PubMed ID: 18560781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medicines under additional monitoring in the European Union.
    Manso G; Neira F; Ortega S; Martín Arias LH; Sainz M; Salgueiro E
    Farm Hosp; 2019 Jan; 43(1):19-23. PubMed ID: 30624169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Navigating stormy waters: 10 years of operation of the European Union Regulatory Network Incident Management Plan for Medicines for Human Use.
    Santoro A; Caplanusi I; Sweeney F; Cappelli B; Nolan L; Straus S; Arlett P
    Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1343-1352. PubMed ID: 32954565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are risk minimization measures for approved drugs in Europe effective? A systematic review.
    Artime E; Qizilbash N; Garrido-Estepa M; Vora P; Soriano-Gabarró M; Asiimwe A; Pocock S
    Expert Opin Drug Saf; 2019 May; 18(5):443-454. PubMed ID: 31032651
    [No Abstract]   [Full Text] [Related]  

  • 40. Impact of the EU Paediatric Medicine Regulation on new anti-cancer medicines for the treatment of children and adolescents.
    Vassal G; de Rojas T; Pearson ADJ
    Lancet Child Adolesc Health; 2023 Mar; 7(3):214-222. PubMed ID: 36682367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.